Company profile
AKEBIA THERAPEUTICS, INC.
NASDAQ:AKBABiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VAFSEO | approved | $21.3MQ2 2026 | 31 | approved |
| EBRIBAFUSP ALFA | phase2 | — | 1 | active |
| PRALICIGUAT | phase2 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (37)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02260193 | phase2 | completed | 2014-09-10 | 2015-07-22 | Akebia Therapeutics | 16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis |
| NCT01906489 | phase2 | completed | 2013-07-23 | 2014-09-03 | Akebia Therapeutics | 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia |
| NCT01381094 | phase2 | completed | 2011-06-15 | 2012-02-16 | Akebia Therapeutics | 42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia |
| NCT06419205 | phase2 | recruiting | 2026-07-30 | 2028-02-01 | Akebia Therapeutics | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G |
| NCT03799848 | phase1 | completed | 2018-06-12 | 2018-10-18 | Akebia Therapeutics | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 215192 | 2024-03-27 | NDA | AKEBIA THERAPEUTICS INC | |||||
Loading… | ||||||||